KDR and colorectal carcinoma: Recently, fruquintinib, a novel anti-VEGFR that targets VEGFR1, VEGFR2, and VEGFR3, demonstrated clinical benefits in heavily pretreated metastatic CRC patients in the FRESCO-2 trial, with a median OS of 7.4 months versus 4.8 months in the placebo group [43].